We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (SNSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (BRSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table summarizes their recent ratings, shedding light on ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company's challenges in establishing its presence in the market for Alzheimer ...

Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company ...

In order from steepest decline to narrowest, the five unloved were Intel(NASDAQ: INTC), MongoDB(NASDAQ: MDB), Biogen(NASDAQ: BIIB), DexCom(NASDAQ: DXCM), and Microchip Technology(NASDAQ: MCHP).

MDB), Biogen (NASDAQ: BIIB), DexCom (NASDAQ: DXCM), and Microchip Technology (NASDAQ: MCHP). Sensus Healthcare (SRTS) was a big mover last session on higher-than-average trading volume.

Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...